Please login to the form below

Not currently logged in
Email:
Password:

US

This page shows the latest US news and features for those working in and with pharma, biotech and healthcare.

Rigel and Ultragenyx claim approvals for rare drugs

Rigel and Ultragenyx claim approvals for rare drugs

Rigel said it intends to launch Tavalisse (fostamatinib) in the US in May and - so far - hasn’t revealed what it intends to charge for the drug. ... inherited form of rickets that affects around 3, 000 children and 15, 000 adults in the US.

Latest news

  • BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

    The US regulator has given the green light to PD-1 inhibitor Opdivo (nivolumab) and CTLA4 inhibitor Yervoy (ipilimumab) as an initial treatment for advanced renal cell carcinoma (RCC) patients on ... Our goal is to provide cancer patients with medicines

  • Incyte/Merck trial failure bodes ill for IDO class Incyte/Merck trial failure bodes ill for IDO class

    The much-touted cancer immunotherapy combination fails to show improvement over Keytruda alone

  • Alkermes slumps as FDA turns down depression drug Alkermes slumps as FDA turns down depression drug

    Alkermes slumps as FDA turns down depression drug. The drug needs to be supported with additional trials and a bioavailability study, says US regulator. ... The US regulator issued a ‘refusal to file’letter to the company yesterday for the drug,

  • Seattle Genetics claims key US approval for Adcetris Seattle Genetics claims key US approval for Adcetris

    Seattle Genetics claims key US approval for Adcetris. Becomes the first new treatment for advanced Hl in more than 40 years. ... Adcetris (brentuximab vedotin), an antibody-drug conjugate, is the first new treatment for this type of lymphoma in more than

  • FDA approves another home genetic testing service FDA approves another home genetic testing service

    The US Food and Drug Administration (FDA) has authorised another one of 23andMe’s home genetic kits, and this one tests if certain women are at an increased risk of developing ... The approval is welcomed news for the online genetics firm, particularly

More from news
Approximately 132 fully matching, plus 1,730 partially matching documents found.

Latest Intelligence

  • The threat of antimicrobial resistance The threat of antimicrobial resistance

    By January 2018, the US Centers for Disease Control and Prevention had reported 29 cases of MCR resistance identified across 15 states of the USA. ... Alongside this, there have been equally important initiatives by the World Health Organization (WHO),

  • Brexit Means Brexit Brexit Means Brexit

    This takes us to the heart of the tensions in Westminster, and also to the caution that characterises the EU27, that doesn’t want to create a new structure for the

  • What makes a meaningful brand? What makes a meaningful brand?

    We must think strategically about what opportunities exist in the marketplace and what makes us unique.

  • Beyond caring: learning from the unsung advocates in cancer care

    Carer? Or advocate? For many people, caring is something that arises organically - it’s what we do when a loved one needs us. ... Furthermore, many of us recognise that there is a degree of inevitable suffering that comes with the pain of a cancer

  • The challenges of making genomics a reality for patients The challenges of making genomics a reality for patients

    The Chief Medical Officer opened her genomics report by telling us genomics is not part of tomorrow, it’s here today.

More from intelligence
Approximately 11 fully matching, plus 463 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 723 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 11 fully matching, plus 819 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics